Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Iranian Journal of Dermatology. 2009; 11 (4): 143-146
in English | IMEMR | ID: emr-109735

ABSTRACT

Pityriasis rosea is an inflammatory skin disorder with a known response to erythromycin. Considering similarities between erythromycin and azithromycin and lesser adverse effects of the latter, in a pilot study, we gave azithromycin to seven patients with pityriasis rosea and observed a noticeable improvement. The aim of this study was to evaluate the efficacy of azithromycin in patients with pityriasis rosea. A double-blind, placebo-controlled clinical trial was performed in our clinic. Sixty patients over a period of 20 months were alternatively assigned to the treatment group or the placebo group. Patients in the treatment group received azithromycin, 250 mg/day, for 14 days. The response was categorized as complete response, partial response, or no response. All patients were followed up for 2 months. Age at presentation, sex, and average duration of the disease were comparable in both groups. Complete response was observed in 19 patients [63.3%] in the treatment group and two in the placebo group [p<0.0001]. Oral azithromycin is effective in treating patients with pityriasis rosea


Subject(s)
Humans , Male , Female , Azithromycin , Treatment Outcome , Double-Blind Method
SELECTION OF CITATIONS
SEARCH DETAIL